CO6470841A2 - SOLID PREPARATION THAT PRESENTS PROPERTY OF IMPROVED DISSOLUTION OF A MEDICINAL PRODUCT FROM THE SAME - Google Patents

SOLID PREPARATION THAT PRESENTS PROPERTY OF IMPROVED DISSOLUTION OF A MEDICINAL PRODUCT FROM THE SAME

Info

Publication number
CO6470841A2
CO6470841A2 CO11164599A CO11164599A CO6470841A2 CO 6470841 A2 CO6470841 A2 CO 6470841A2 CO 11164599 A CO11164599 A CO 11164599A CO 11164599 A CO11164599 A CO 11164599A CO 6470841 A2 CO6470841 A2 CO 6470841A2
Authority
CO
Colombia
Prior art keywords
solid preparation
same
medicinal product
improved dissolution
property
Prior art date
Application number
CO11164599A
Other languages
Spanish (es)
Inventor
Wataru Hoshina
Shigeyuki Marunaka
Makoto Fukuta
Original Assignee
Takeda Pharmaceuticals Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43032637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6470841(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Company Ltd filed Critical Takeda Pharmaceuticals Company Ltd
Publication of CO6470841A2 publication Critical patent/CO6470841A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona una preparación sólida que comprende (i) un compuesto representado por la fórmula (I)En la cual cada símbolo tiene la definición dada en la memoria descriptiva, o una sal de la misma; (ii) un alcohol de azúcar y (iii) un antagonista de calcio; la cual es superior en propiedad de disolución y estabilidad.A solid preparation is provided comprising (i) a compound represented by the formula (I) In which each symbol has the definition given in the specification, or a salt thereof; (ii) a sugar alcohol and (iii) a calcium antagonist; which is superior in property of dissolution and stability.

CO11164599A 2009-04-30 2011-11-30 SOLID PREPARATION THAT PRESENTS PROPERTY OF IMPROVED DISSOLUTION OF A MEDICINAL PRODUCT FROM THE SAME CO6470841A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009111381 2009-04-30
JP2010068625 2010-03-24

Publications (1)

Publication Number Publication Date
CO6470841A2 true CO6470841A2 (en) 2012-06-29

Family

ID=43032637

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11164599A CO6470841A2 (en) 2009-04-30 2011-11-30 SOLID PREPARATION THAT PRESENTS PROPERTY OF IMPROVED DISSOLUTION OF A MEDICINAL PRODUCT FROM THE SAME

Country Status (24)

Country Link
EP (1) EP2424501A2 (en)
JP (1) JP5666471B2 (en)
KR (1) KR101797776B1 (en)
CN (1) CN102481248B (en)
AU (1) AU2010242308A1 (en)
BR (1) BRPI1014388A2 (en)
CA (1) CA2760073A1 (en)
CL (1) CL2011002662A1 (en)
CO (1) CO6470841A2 (en)
CR (1) CR20110581A (en)
DO (1) DOP2011000329A (en)
EA (1) EA201171329A1 (en)
EC (1) ECSP11011494A (en)
GE (1) GEP20135940B (en)
IL (1) IL215962A0 (en)
MA (1) MA33280B1 (en)
MX (1) MX2011011011A (en)
MY (1) MY158158A (en)
NZ (1) NZ596395A (en)
PE (1) PE20120315A1 (en)
SG (1) SG175794A1 (en)
TW (1) TWI438201B (en)
WO (1) WO2010126168A2 (en)
ZA (1) ZA201108375B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL236001B1 (en) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Complex pharmaceutical composition comprising candesartan cilexetil and amlodipine, its preparation method and the unit dosage form comprising said composition,
KR101535586B1 (en) * 2014-08-01 2015-07-09 에스케이케미칼주식회사 Pharmaceutical preparation comprising amorphous or metastable form of rivaroxaban
KR101806004B1 (en) * 2015-01-30 2017-12-08 씨제이헬스케어 주식회사 A pharmaceutical composition comprising candesartan and amlodipine
CN106668016B (en) * 2015-11-11 2020-06-23 江苏先声药业有限公司 Solid preparation of azilsartan and amlodipine besylate composition and preparation method thereof
JP2017210435A (en) * 2016-05-25 2017-11-30 ダイト株式会社 Method for producing irbesartan and amlodipine besylate-containing tablet
JP2019001782A (en) * 2017-06-14 2019-01-10 東和薬品株式会社 Bilayer tablet
JP7101464B2 (en) * 2017-09-28 2022-07-15 エルメッド株式会社 A method for improving the quality of azilsartan or a salt thereof and amlodipine or a salt-containing tablet thereof, and azilsartan or a salt thereof and amlodipine or a salt-containing tablet thereof and a method for producing the same.
CN108210472A (en) * 2017-12-15 2018-06-29 蚌埠丰原医药科技发展有限公司 A kind of Cilnidipine solid dispersions tablet and preparation method thereof
CN108685925B (en) * 2018-05-15 2019-12-06 徐州医科大学 application of compound AB-38b in preparation of medicine for treating diabetic nephropathy
JP2020075869A (en) * 2018-11-05 2020-05-21 日本ケミファ株式会社 Tablet containing angiotensin ii receptor antagonist and calcium antagonist as active ingredients
JP2020090471A (en) * 2018-12-07 2020-06-11 ニプロ株式会社 Pharmaceutical composition containing azilsartan and amlodipine and method for producing the same
JP7206872B2 (en) * 2018-12-07 2023-01-18 ニプロ株式会社 Pharmaceutical composition containing azilsartan and amlodipine and method for producing the same
JP7441105B2 (en) * 2020-03-31 2024-02-29 日本ジェネリック株式会社 Film-coated tablets containing azilsartan and amlodipine besilate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2814513B2 (en) * 1988-02-03 1998-10-22 吉富製薬株式会社 Pharmaceutical composition with improved dissolution
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
JP3057471B2 (en) * 1993-06-07 2000-06-26 武田薬品工業株式会社 Agent for preventing or treating angiotensin II-mediated diseases
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
WO2002074340A1 (en) * 2001-03-16 2002-09-26 Takeda Chemical Industries, Ltd. Process for producing sustained release preparation
CA2468827A1 (en) * 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
JP4743684B2 (en) * 2002-05-22 2011-08-10 塩野義製薬株式会社 Method for improving dissolution of poorly water-soluble drugs
EP1564213A4 (en) 2002-11-22 2009-05-27 Takeda Pharmaceutical Imidazole derivative, process for producing the same, and use
WO2005030740A1 (en) 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
CA2550012A1 (en) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same and use
TWI396686B (en) 2004-05-21 2013-05-21 Takeda Pharmaceutical Cyclic amide derivative, and its production and use
JP2006321726A (en) * 2005-05-17 2006-11-30 Sysmex Corp Method for controlling elution property of tablet
JP5063370B2 (en) * 2005-06-27 2012-10-31 第一三共株式会社 Method for preparing wet granulated pharmaceutical
CA2613417C (en) * 2005-06-27 2011-11-29 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
DE102005031577A1 (en) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmaceutical dosage forms containing a combination of nifedipine and / or nisoldipine and an angiotensin II antagonist
TWI409064B (en) * 2007-03-29 2013-09-21 Daiichi Sankyo Co Ltd Pharmaceutical composition
AR073380A1 (en) * 2008-09-25 2010-11-03 Takeda Pharmaceutical SOLID PHARMACEUTICAL COMPOSITION. MULTI-PAD TABLET

Also Published As

Publication number Publication date
IL215962A0 (en) 2012-01-31
TW201041873A (en) 2010-12-01
GEP20135940B (en) 2013-10-10
CN102481248A (en) 2012-05-30
KR20120026060A (en) 2012-03-16
EP2424501A2 (en) 2012-03-07
JP5666471B2 (en) 2015-02-12
JP2012525323A (en) 2012-10-22
MY158158A (en) 2016-09-15
WO2010126168A2 (en) 2010-11-04
MX2011011011A (en) 2011-11-02
CR20110581A (en) 2012-01-19
CL2011002662A1 (en) 2012-06-15
AU2010242308A1 (en) 2011-12-01
DOP2011000329A (en) 2011-11-15
CA2760073A1 (en) 2010-11-04
WO2010126168A3 (en) 2011-03-03
MA33280B1 (en) 2012-05-02
PE20120315A1 (en) 2012-04-07
KR101797776B1 (en) 2017-11-14
ECSP11011494A (en) 2011-12-30
ZA201108375B (en) 2013-01-30
EA201171329A1 (en) 2012-05-30
TWI438201B (en) 2014-05-21
NZ596395A (en) 2013-06-28
BRPI1014388A2 (en) 2016-04-05
SG175794A1 (en) 2011-12-29
CN102481248B (en) 2013-12-11

Similar Documents

Publication Publication Date Title
CO6470841A2 (en) SOLID PREPARATION THAT PRESENTS PROPERTY OF IMPROVED DISSOLUTION OF A MEDICINAL PRODUCT FROM THE SAME
CL2014003171A1 (en) Lyophilized composition comprising at least one benzodiazepine of formula (i), at least one hygroscopic excipient selected from disacarides and dextran; method of preparation of the pharmaceutical composition.
BR112015011112A2 (en) oligomeric compound, oligomer, pharmaceutical composition, use of the oligomeric compound, method of synthesis of an oligomeric compound and method of treating a disease.
UA111717C2 (en) ORAL INTRODUCTION AND METHYLNALTREXON LIPOPHILIC SALTS
DK2068839T3 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING NILOTINIB OR SALT THEREOF
DK3045164T3 (en) Aqueous pharmaceutical compositions containing borate-polyol complexes
ES2531516T3 (en) Use of Escina
ECSP088716A (en) MEDICINES CONTAINING FLUOROQUINOLONES
EP3228311A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
EA201300990A1 (en) PARENTAL INTRODUCTION OF TAPENTADOL
EA201600442A1 (en) SOFT PHARMACEUTICAL COMPOSITION ON WATER BASIS CONTAINING TAPENTADOL
ECSP11011001A (en) SOLID PHARMACEUTICAL COMPOSITION
EA201200616A1 (en) DERIVATIVES 2-OXO-1-PIRROLIDININILIMIDAZOTHIAADIA ASOL
MX2012001691A (en) Orally disintegrating compositions of linaclotide.
ES2415029A8 (en) Pharmaceutical composition and use of an antibody to prepare a medicament intended to inhibit the production or amplify the elimination of the P24 protein.
AR089486A1 (en) PHARMACEUTICAL PREPARATION INCLUDING b-CYCLODEXTRINE REPLACED
WO2012017448A3 (en) Salts of lapatinib
EA201200485A1 (en) ORAL FALLING PHARMACEUTICAL DRUG FORM CONTAINING AIPIPRAZOL
EA201001353A1 (en) GIDROBROMID IUBRADINA
ECSP11010856A (en) SOLID PHARMACEUTICAL COMPOSITION
TR200909785A1 (en) Pharmaceutical compositions containing cefdinir as the active agent.
ATE530164T1 (en) AQUEOUS PHARMACEUTICAL PREPARATION
AR067498A1 (en) STABLE PHARMACEUTICAL COMPOSITION OF A HYDROSOLUBLE SALT OF VINORRELBINA
EA201290285A1 (en) MULTILAYER PHARMACEUTICAL COMPOSITION DISPENSABLE IN WATER, CONTAINING A COMBINATION OF ANTI-MALARY
유영경 et al. Initial Experience of Laparoscopic Liver Resection at Catholic University Seoul St. Mary's Hospital

Legal Events

Date Code Title Description
FC Application refused